

Results of Statistical Analysis

End point title: Number of Subjects With Sustained Accumulation of Disability (SAD)

| | |
|---|---|
| Statistical analysis title | Alemtuzumab Treatment CAMMS323 Extension |
| Statistical analysis description | The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method. |
| Comparison groups | Alemtuzumab Treatment CAMMS323 Extension |
| Number of subjects included in analysis | 376 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| Method | |
| Parameter type | Percentage with SAD |
| Point estimate | 22.33 |
| Confidence interval | |
| level | 95% |
| sides | 2-sided |
| lower limit | 18.33 |
| upper limit | 27.06 |
| Statistical analysis title | Alemtuzumab Treatment CAMMS324 Extension |
| Statistical analysis description | The percentage and 95% CI of the subjects with SAD were estimated by the Kaplan Meier method. |
| Comparison groups | Alemtuzumab Treatment CAMMS324 Extension |
| Number of subjects included in analysis | 426 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| Method | |
| Parameter type | Percentage with SAD |
| Point estimate | 29.69 |
| Confidence interval | |
| level | 95% |
| sides | 2-sided |
| lower limit | 25.42 |
| upper limit | 34.49 |